Search results
Results from the WOW.Com Content Network
Ly6 proteins are characterized by the LU domain.Typically, they contain one LU domain, but some members of the family have multiple LU domains.The LU domain consists of 60-80 AA and contains 10 cysteines arranged in a specific pattern that allows the creation of 5 disulfide bridges which in turn allow the formation of a three-fingered (3F) structural motif.
They share some of the same cell marker proteins, chromosome abnormalities, and gene mutations that are found in CLL. [37] [38] CLL-type MBL can be separated into two groups: Low-count MBL has monoclonal B-cell blood counts of <0.5x10 9 cells/liter (i.e. 0.5x10 9 /L) High-count MBL has blood monoclonal B-cell counts ≥0.5x10 9 /L but <5x10 9 ...
For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give a diagnosis, while other tumor markers have the opposite functionality. Therefore it's important to follow the guidelines of the specific tumor marker. Tumor markers are mainly used in clinical medicine to support a ...
Lymphocyte antigen 6E is a protein that in humans is encoded by the LY6E gene. [5] [6] [7] Increased expression of Ly6E is associated with poor survival outcome in multiple malignancies as determined by a survey of more than 130 published clinical studies of gene expression studies on cancer tissue samples and adjacent normal tissues. [8]
A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule." [18] In cancer research and medicine, biomarkers are used in three primary ways: [19] To help diagnose conditions, as in the case of identifying early stage cancers (diagnostic)
The Ki-67 score closely correlates with other proliferation markers, and has been shown to have prognostic and predictive value for many different tumor types. [9] Similarly, proliferating cell nuclear antigen (PCNA) is a protein associated with cell proliferation that is upregulated in proliferating cells, making it another useful antigen for ...
The CD nomenclature was proposed and established in the 1st International Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Paris in 1982. [4] [5] This system was intended for the classification of the many monoclonal antibodies (mAbs) generated by different laboratories around the world against epitopes on the surface molecules of leukocytes (white blood cells).
Tumor stroma and extracellular matrix in hypoxia. Tumor hypoxia is the situation where tumor cells have been deprived of oxygen.As a tumor grows, it rapidly outgrows its blood supply, leaving portions of the tumor with regions where the oxygen concentration is significantly lower than in healthy tissues.